ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile Inflammatory Arthritis"

  • Abstract Number: 2676 • ACR Convergence 2025

    Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab

    Anu Balakrishnan1, Asif Khan2, Shivika Guleria3, Fareha Umam4, Naveen R5, Priyansh Jain2, Lekshmi Minikumari Rahulan2, Rudrarpan Chatterjee6 and Amita Aggarwal7, 1Sanjay Gandhi Post Graduate Institute, India, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, 3SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, 4Dept of Clinical Immunology and Rheumatology, SGPGIMS, Lucknow, Uttar Pradesh, India, 5Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 6Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, 7Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Tofacitinib is a JAK inhibitor that has been approved for treatment of polyarticular Juvenile idiopathic arthritis. However, data on its use in juvenile spondyloarthropathy…
  • Abstract Number: 2130 • ACR Convergence 2025

    Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom

    Ashwini Batchu Prithvi, Chaitra Govardhan, Bushra Aladaileh and Athimalaipet V Ramanan, Bristol Royal Hospital for Children, Bristol, United Kingdom

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a chronic disease that results in significant morbidity and mortality in children1. Improved understanding of the pathophysiology of…
  • Abstract Number: 1274 • ACR Convergence 2025

    Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation

    Andres Perez Hurtado1, Jose Ivorra Cortes2, ELENA GRAU GARCIA3, Miguel Simeo Vinaixa4, Iago Alcantara Alvarez4, Belen Villanueva Manes5, Alba Maria Torrat Noves6, Daniel Ramos Castro7, Pablo Muñoz Martinez4, Laura mas sanchez8, Berta López Montesinos9, Lucía Lacruz Pérez10 and José Andrés Román Ivorra11, 1Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, 2Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, 3HUP La Fe, Valencia, Comunidad Valenciana, Spain, 4Rheumatology Department. HUP La Fe, Valencia, Spain, 5Hospital La Fe, València, Spain, 6Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, 7Hospital Universitari i Politecnic La Fe, Valencia, Spain, 8Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, 9Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, 10Pediatric Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 11Hospital Universitari i Politècnic La Fe, Valencia, Spain

    Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…
  • Abstract Number: 0424 • ACR Convergence 2025

    Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India

    Sreelekha Kambhampati1, keerthi vardhan yerram2, Kavitha Meesala1, Phani Kumar Devarasetti2 and Liza rajasekhar3, 1Nizams institute of medical sciences, hyderabad, India, 2Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, 3Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic arthritis in children, but its diagnosis is often challenging due to overlapping symptoms with other…
  • Abstract Number: 0415 • ACR Convergence 2025

    The Impact of Social Vulnerability Index Scores in Pediatric Uveitis

    Minal Aundhia1, Pankaj Rajdeo2, Michael Wagner1, Alexandra Duell1, Megan Quinlan-Waters3, Virginia Miraldi Utz1 and Sheila Angeles-Han4, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, CCHMC, 4Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children with uveitis as the most common extra-articular manifestation. Uveitis can lead to…
  • Abstract Number: 0397 • ACR Convergence 2025

    Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom

    Chaitra Govardhan1, Ashwini Batchu Prithvi1, Bushra Aladaileh1, Elizabeth Cattermole2, Farrag Abdelsattar2, Catherine Guly2, Jessy Choi3, Johannes Keller2 and Athimalaipet V Ramanan1, 1Bristol Royal Hospital for Children, Bristol, United Kingdom, 2Bristol Eye Hospital, Bristol, United Kingdom, 3Sheffield Children's Hospital, Sheffield, United Kingdom

    Background/Purpose: Cataract is one of the most common and visually debilitating complications of paediatric uveitis developing as a consequence of chronic inflammation and steroid use.…
  • Abstract Number: 0393 • ACR Convergence 2024

    Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA

    Marianne Kerski1, Smriti Mohan1, Cynthia Vizcaya2, Reema Sutariya3, Weibin Bao3 and Matthew Stoll4, 1University of Michigan, Ann Arbor, MI, 2Novartis Pharmaceutical Corporation, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
  • Abstract Number: 1309 • ACR Convergence 2024

    Bridging the Gap: Evaluating Ophthalmology Training Amongst Pediatric Rheumatology Fellows

    Jully Padam1, Tzielan Lee2 and Rajdeep Pooni3, and Childhood Arthritis and Rheumatology Research Alliance., 1Stanford University, Redwood City, CA, 2Stanford University School of Medicine, Palo Alto, CA, 3Stanford University, Palo Alto, CA

    Background/Purpose: The scarcity of literature surrounding ophthalmology training within non-ophthalmology specialties is striking. Chan et al. highlighted this gap revealing a discomfort among family medicine…
  • Abstract Number: 1771 • ACR Convergence 2024

    Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics

    Mireia Lopez Corbeto1, yolanda Guillen2, Irene Bonafonte3, Nuria Palau4, Raül Tortosa4, Estefanía Moreno Ruzafa1, Antonio Julia5 and Sara Marsal6, 1Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, 2Imidomics, Inc, Barcelona, Spain, 3Berufserfahrung: Helmholtz Munich, Barcelona, Spain, 4Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, 5Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 6Vall Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…
  • Abstract Number: 1915 • ACR Convergence 2024

    Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting

    Martha Delgado1, Cassidy Hernandez-Tamayo2, Melissa Wilson2 and Leanna Wise3, 1Los Angeles General Hospital/Keck Medicine of USC, Costa Mesa, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3LAGMC/Keck Medicine of USC, Los Angeles, CA

    Background/Purpose: Timely reproductive health conversations in the rheumatology outpatient setting are essential for optimal maternal-fetal health; however, the literature suggests that these conversations happen for…
  • Abstract Number: 1945 • ACR Convergence 2024

    The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates

    John Bridges1, Eileen Rife2, Randy Cron3, Livie Timmerman4, Linda McAllister5, Annelle Reed6, Carolyn Smith7, Emily Smitherman3, Matthew Stoll3, Bethany Walker5 and Melissa Mannion3, 1University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 2University of Alabama Birmingham, Vestavia Hills, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama at Birmingham, Gardendale, AL, 5Children's of Alabama, Trussville, AL, 6Children's of Alabama, Tuscaloosa, AL, 7Children's of Alabama, Birmingham, AL

    Background/Purpose: The transition period from pediatric to adult-oriented rheumatology care is a high-risk time for disease flare and poor outcomes.  We previously demonstrated implementation of…
  • Abstract Number: 0359 • ACR Convergence 2023

    Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment

    Chelsea Vallejos1, Jennifer Cooper2 and Ingrid Pan1, 1Children's Hospital Colorado, Aurora, CO, 2University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Adalimumab therapeutic drug monitoring (TDM) using established trough concentrations is not standard practice in JIA patients, unlike IBD. No specific guidelines outline a therapeutic…
  • Abstract Number: 0364 • ACR Convergence 2023

    Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis

    Adam Mayer1, Timothy G. Brandon2, Pamela F. Weiss3 and on behalf of the JAXSPERT members2, 1University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…
  • Abstract Number: 0831 • ACR Convergence 2023

    Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study

    Sarah Ringold1, George Tomlinson2, Laura Schanberg3, vincent del gaizo4, Katherine Murphy5, Brian Feldman6, Mei-Sing Ong7, Marc Natter8, Yukiko Kimura9 and For The CARRA Registry Investgators4, 1Seattle Children's Hospital, Seattle, WA, 2University of Toronto, Toronto, ON, Canada, 3Duke University School of Medicine, Durham, NC, 4CARRA, Inc, Washington, DC, 5Non-clinical, New Orleans, LA, 6The Hospital for Sick Children, Toronto, ON, Canada, 7Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, 8Harvard Medical School, Boston, MA, 9Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
  • Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium

    Using the Electronic Health Record to Identify Subjects with Rheumatic Disease

    Alysha Taxter1, Matthew Basiaga2, Rajdeep Pooni3, Caitlan Pinotti4, Lisa Buckley5 and CARRA Registry Investigators6, 1Nationwide Children's Hospital, Columbus, OH, 2Mayo Clinic, Rochester, MN, 3Stanford University, Palo Alto, CA, 4Duke, Durham, NC, 5Vanderbilt University Medical Center, Nashville, TN, 6CARRA, Washington, DC

    Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology